Spectral Medical Inc. (EDT.TO)
- Previous Close
0.4250 - Open
0.4300 - Bid 0.4450 x --
- Ask 0.4500 x --
- Day's Range
0.4300 - 0.4500 - 52 Week Range
0.2250 - 0.6700 - Volume
12,500 - Avg. Volume
86,709 - Market Cap (intraday)
125.359M - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0600 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 19, 2011
- 1y Target Est
1.80
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
spectraldx.com29
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: EDT.TO
Performance Overview: EDT.TO
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EDT.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EDT.TO
Valuation Measures
Market Cap
118.39M
Enterprise Value
124.00M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
74.09
Price/Book (mrq)
--
Enterprise Value/Revenue
77.60
Enterprise Value/EBITDA
-8.89
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-78.75%
Return on Equity (ttm)
--
Revenue (ttm)
1.6M
Net Income Avi to Common (ttm)
-15.51M
Diluted EPS (ttm)
-0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
3.56M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.82M
Research Analysis: EDT.TO
Company Insights: EDT.TO
EDT.TO does not have Company Insights